Pasi A. Jänne, MD, PhD - Expanding Pathways of Care for HER2-Positive Metastatic NSCLC: Beyond Mutation to Overexpression

Please visit answersincme.com/GRK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses the role of antibody–drug conjugates (ADCs) in the treatment of HER2-positive metastatic non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Recognize the difference between HER2 overexpression and HER2 mutation when managing patients with advanced NSCLC; Review the efficacy and safety of HER2-directed antibody–drug conjugates (ADCs) for the treatment of HER2-overexpressing metastatic NSCLC; and Outline clinical approaches to optimize the management of patients with HER2-overexpressing metastatic NSCLC.

There are no comments yet.

Please log in to write the first comment.